Rep. Correa Leads Bipartisan Push to Create VA Centers for Psychedelic-Assisted Therapy
A house committee must act next: committee consideration.
Scores run from -100 (strongly harmful) to +100 (strongly beneficial) for each group, combining impact, certainty, scope, and duration ratings of 1-5. How impact scoring works
Veterans dealing with PTSD, depression, chronic pain, substance use disorders, and other serious conditions could gain access to promising new treatments like psilocybin and MDMA-assisted therapy through specialized VA centers. While these therapies have shown strong results in clinical trials, the program would initially serve a small share of the veteran population since only five or more centers would be created. Over time, findings from these centers could reshape how the entire VA system treats mental health.
“Subject to the availability of appropriations for such purpose, the Secretary shall establish and operate innovative therapies centers of excellence at the locations designated pursuant to paragraph (1).”
Referred to the Subcommittee on Health.
Sent to a congressional committee for expert review. The committee decides whether this bill moves forward.
Referred to the House Committee on Veterans' Affairs.
Introduced in House
The bill was officially filed and given a number. It now enters the legislative queue.
New legislation introduced in Congress would require the VA to designate medical facilities as 'innovative therapies centers of excellence,' increasing federal funding to study therapeutic uses of psychedelics like MDMA and psilocybin for veterans struggling with PTSD and depression.
Senators Ruben Gallego and Dave McCormick introduced the Senate version of a bill to mandate the VA establish centers of excellence for psychedelic-assisted treatments. The bill targets conditions including PTSD, substance use disorder, and chronic pain using substances like MDMA and ibogaine.
The 'Innovative Therapies Centers of Excellence Act of 2025' (S. 4031) seeks to designate at least five VA facilities as specialized hubs for research and clinical care, appropriating $30 million annually for treatments involving MDMA, psilocybin, and DMT.
No votes recorded for this bill yet.
Document Type
Congressional Bill
Official Title
Innovative Therapies Centers of Excellence Act of 2025
Analysis generated by AI. Always verify with official sources.